earnings
confidence high
sentiment neutral
materiality 0.75
Schrödinger Q2 rev $47.3M (+35% YoY); net loss $54.0M; updates FY guidance
Schrodinger, Inc.
2024-Q2 EPS reported
-$1.50
revenue$83,932,000
- Total revenue $47.3M (+35% YoY), software rev $35.4M (+21%), drug discovery $11.9M (+104%). Net loss $54.0M vs income $4.3M YoY.
- FY2024 guidance: software rev growth 6-13%, drug discovery $30-35M, op expense growth 8-10%, cash use above FY2023.
- Co-founded Morphic to be acquired by Lilly for ~$3.2B; Schrödinger holds 834,968 shares and low single-digit royalties.
- Launched predictive toxicology platform with $10M Gates Foundation grant and NVIDIA AI integration.
- Pipeline: SGR-1505 Phase 1 data 1H25; SGR-2921 Fast Track, data 2H25; SGR-3515 Phase 1 started, data 2H25.